871P - Incidence and pattern of second neoplasms in patients diagnosed with invasive transitional carcinoma of the urinary tract

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Urothelial Cancers
Aetiology, Epidemiology, Screening and Prevention
Basic Scientific Principles
Presenter Andrea Vethencourt
Citation Annals of Oncology (2014) 25 (suppl_4): iv280-iv304. 10.1093/annonc/mdu337
Authors A.C. Vethencourt1, A. Gómez de Liaño Lista2, G. Sancho Pardo1, J. Palou3, D. Páez1, L.P. Del Carpio1, C. Arqueros1, N. Dueñas1, A.C. Virgili1, A. Barnadas1, P. Maroto1
  • 1Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 2Medical Oncology, Hospital de Sant Pau i La Santa Creu, 08025 - Barcelona/ES
  • 3Urology Department, Fundacio Puigvert, 08025 - Barcelona/ES



Few inherited familial syndromes include transitional cell cancer; however the field carcinogenesis is a common problem for patients diagnosed of transitional cell carcinoma. Besides smoking, other risk factors are associated with developing second neoplasms such as alcohol intake and aging. While there are some published studies about secondary smoking-related tumours in this population, data about the incidence of other not-smoking related tumours is limited. The objective of this study was to analyse the cumulative incidence of second neoplasms in this population and determine the type of second neoplasms: urinary tract vs not-related urinary tract.


Retrospective analysis of 629 patients diagnosed with invasive transitional cell carcinoma of the urinary tract treated in a single medical center from 1999 to 2012. Patients with a follow-up shorter than 6 months were excluded. Synchronic prostate carcinoma were not included, tumours included in our analyses were those diagnosed during the follow-up. Cumulative incidence of secondary tumours was calculated by kaplan-meier.


Median age of patients was 67 years (30-87). Median follow-up time was 60 months. There were 45 patients who developed a second neoplasm (8%); 32 corresponded to non-urothelial tumours (71%) and 13 urothelial tumours (29%). The actuarial cumulative incidence of a second neoplasm was 27% at 10 years. Incidence of not-urinary tumours was 19% at 10 years. There were 14 cases of lung cancer (31,1 %) (2 oat cell and 12 NSCLC) 3 colon cancers (6,7%), 2 cancers of the rectum (4,4%), 2 renal cancers (4,4%), 2 Hepatocellular carcinomas (4,2%), 2 haematological tumours (4,4%), and 1 case of each of the following tumours: GIST, prostate, parotid, biliary track, glottis, thyroid, vagina and brain. The interval between the diagnosis of urothelial cancer and the second neoplasm was on average 46,88 months. Smoking was common in all patients with second neoplasms (93,3%).


Diagnosis of second neoplasms is a major concern for this population, which is heavily exposed to risk factors, such as smoking. Specific follow-up is required as well as programs for smoking cessation.


All authors have declared no conflicts of interest.